The case for SmartTrack
Michael Paik, Ashlesh Sharma, Arthur Meacham, Giulio Quarta, Philip D Coleridge Smith, John M. Trahanas, Brian Neil Levine, Mary Ann Hopkins, Barbara Rapchak, Lakshminarayanan Subramanian · 2009
Abstract—Nearly 40 million people in Africa suffer from HIV/AIDS. African governments and international aid agencies have been working to combat this epidemic by vigorously promoting Highly Active Anti-Retroviral Therapy (HAART) programs. Despite the enormous subsidies offered by governments along with free Anti-RetroViral (ARV) drugs supplied by agencies, the introduction and implementation of HAART programs on a large scale has been limited by two fundamental problems: (a) lack of adherence to the ARV therapy regimen; (b) lack of accountability in drug distribution due to theft, corruption and counterfeit medication. In this paper, we motivate the case for SmartTrack, a telehealth project which aims to address these two problems facing HAART programs. The goal of SmartTrack is to create a highly reliable, secure and ultra low-cost cellphone-based distributed drug information system that can be used for tracking the flow and consumption of ARV drugs in HAART programs. In this paper, we assess the potential benefit of SmartTrack using a detailed needs-assessment study performed in Ghana, using interviews with 516 HIV-positive rural patients in a number of locations across the country. We find that a system like SmartTrack would immensely benefit both patients and healthcare providers, and can ultimately lead to improved patient outcomes and better accountability. Index Terms—SmartTrack, telehealth, drug tracking, drug monitoring, patient adherence I.